research use only
Cat.No.S2653
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other Topoisomerase Inhibitors | Camptothecin (CPT) (S)-10-Hydroxycamptothecin Beta-Lapachone Amonafide Voreloxin (SNS-595) hydrochloride Ellagic acid Genz-644282 Hydroxy Camptothecine Rubitecan Eleutherin |
|
In vitro |
4-Methylpyridine : 10 mg/mL
DMSO
: 0.78 mg/mL
(2.14 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 363.37 | Formula | C20H17N3O4
|
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 91421-43-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | 9-AC, Aminocamptothecin, 9-amino-20(S)-camptothecin | Smiles | CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O | ||
| Targets/IC50/Ki |
Topo I
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04909489 | Unknown status | Traditional Chinese Medicine|Dyslipidemias|Syndrome |
Dongzhimen Hospital Beijing |
April 21 2021 | -- |
| NCT03978624 | Active not recruiting | Bladder Cancer |
UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme LLC|Syndax Pharmaceuticals |
September 23 2020 | Phase 2 |
| NCT00003154 | Completed | Lung Cancer |
Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
January 1998 | Phase 2 |
| NCT00002745 | Completed | Lymphoma |
National Cancer Institute (NCI) |
April 1996 | Phase 2 |
| NCT00251368 | Completed | Leukemia Myelocytic Acute|Acute Lymphocytic Leukemia |
Dana-Farber Cancer Institute|Brigham and Women''s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital |
January 1995 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.